These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 3262173)

  • 1. Immunocompetence of tissue infiltrating lymphocytes in bladder tumors.
    Tsujihashi H; Matsuda H; Uejima S; Akiyama T; Kurita T
    J Urol; 1988 Oct; 140(4):890-4. PubMed ID: 3262173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of natural killer cells in bladder tumor.
    Tsujihashi H; Matsuda H; Uejima S; Akiyama T; Kurita T
    Eur Urol; 1989; 16(6):444-9. PubMed ID: 2591428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoresponse of tissue infiltrating lymphocytes in bladder tumors.
    Tsujihashi H; Matsuda H; Uejima S; Akiyama T; Kurita T
    J Urol; 1989 Jun; 141(6):1467-70. PubMed ID: 2657115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer.
    Mizutani Y; Yoshida O
    J Urol; 1991 May; 145(5):1082-7. PubMed ID: 2016797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro enhancement of natural killer cell activity by BCG and the antagonistic inhibition of the susceptibility of K562 cells to lysis by peripheral blood lymphocytes in patients with urinary bladder tumor.
    Mizutani Y; Yoshida O
    Int J Urol; 1994 Mar; 1(1):49-56. PubMed ID: 7627838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells.
    Radrizzani M; Gambacorti-Passerini C; Parmiani G; Fossati G
    Cancer Immunol Immunother; 1989; 28(1):67-73. PubMed ID: 2462469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer.
    Mizutani Y; Okada Y; Yoshida O; Bonavida B
    Cancer Biother Radiopharm; 1996 Dec; 11(6):385-91. PubMed ID: 10851499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
    Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
    Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
    Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
    J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes.
    Mizutani Y; Yoshida O; Miki T
    J Urol; 1999 Dec; 162(6):2170-5. PubMed ID: 10569614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of natural killer activity of lymphocytes infiltrating human lung cancers.
    Anderson TM; Ibayashi Y; Holmes EC; Golub SH
    Cancer Immunol Immunother; 1987; 25(1):65-8. PubMed ID: 3109739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
    Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A
    J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
    Komatsu F; Kihara K
    Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
    Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
    Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific and non-specific lymphocyte cytotoxicity in colon carcinoma.
    Vose BM; Gallagher P; Moore M; Schofield PF
    Br J Cancer; 1981 Dec; 44(6):846-55. PubMed ID: 6976792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
    Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
    Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients.
    Nakamura H; Ishiguro K; Mori T
    Cancer; 1988 Dec; 62(12):2489-97. PubMed ID: 3142676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer and lymphokine-activated killer cell-mediated cytotoxicity in patients with oral cancer.
    Gangal SG; Tatake RJ; Krishnan N; Mukhopadhyaya R; Naik SL; Fakih AR; Rao RS
    Semin Surg Oncol; 1989; 5(5):347-50. PubMed ID: 2814145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood lymphocytes from thermal injury patients are defective in their ability to generate lymphokine-activated killer (LAK) cell activity.
    Klimpel GR; Herndon DH; Stein MD
    J Clin Immunol; 1988 Jan; 8(1):14-22. PubMed ID: 2966807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.